Compare · DXCM vs MODD
DXCM vs MODD
Side-by-side comparison of DexCom Inc. (DXCM) and Modular Medical Inc. (MODD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and MODD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 1119.8x MODD ($25.1M).
- Over the past year, DXCM is down 14.9% and MODD is down 79.9% - DXCM leads by 65.0 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 4 for MODD).
- DXCM has more recent analyst coverage (25 ratings vs 0 for MODD).
- Company
- DexCom Inc.
- Modular Medical Inc.
- Price
- $72.84+0.38%
- $4.79+3.79%
- Market cap
- $28.11B
- $25.1M
- 1M return
- +20.73%
- +21.24%
- 1Y return
- -14.94%
- -79.90%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 26
- 4
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Modular Medical Inc.
Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps using technology to enhance pump adoption in the diabetes marketplace. The company is headquartered in San Diego, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest MODD
- Modular Medical Launches New Website for Pivot Tubeless Insulin Patch Pump
- Modular Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Officer Diperna Paul
- SEC Form 4 filed by Chief Operating Officer Schmid Kevin
- SEC Form EFFECT filed by Modular Medical Inc.
- Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event Titled "From FDA Wins to Scaling Manufacturing - What Investors Should Watch." Featuring Modular Medical CEO - Friday, May 1, 2026
- SEC Form S-3 filed by Modular Medical Inc.
- Modular Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Modular Medical Inc.
- Modular Medical Announces Pricing of $3.4 Million Registered Direct Offering of Common Stock